0001104659-22-001638.txt : 20220105
0001104659-22-001638.hdr.sgml : 20220105
20220105194142
ACCESSION NUMBER: 0001104659-22-001638
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220103
FILED AS OF DATE: 20220105
DATE AS OF CHANGE: 20220105
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hoffman Michael B
CENTRAL INDEX KEY: 0001290208
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39202
FILM NUMBER: 22513173
BUSINESS ADDRESS:
BUSINESS PHONE: (203) 413-2200
MAIL ADDRESS:
STREET 1: 1 GREENWICH OFFICE PARK
CITY: GREENWICH
STATE: CT
ZIP: 06831
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Annovis Bio, Inc.
CENTRAL INDEX KEY: 0001477845
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 262540421
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1055 WESTLAKES DRIVE, SUITE 300
CITY: BERWYN
STATE: PA
ZIP: 19312
BUSINESS PHONE: 610-727-3913
MAIL ADDRESS:
STREET 1: 1055 WESTLAKES DRIVE, SUITE 300
CITY: BERWYN
STATE: PA
ZIP: 19312
FORMER COMPANY:
FORMER CONFORMED NAME: QR Pharma, Inc.
DATE OF NAME CHANGE: 20091202
4
1
tm221949-2_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2022-01-03
0
0001477845
Annovis Bio, Inc.
ANVS
0001290208
Hoffman Michael B
C/O ANNOVIS BIO, INC.
1055 WESTLAKES DRIVE, SUITE 300
BERWYN
PA
19312
1
0
1
0
Common Stock
2022-01-04
4
M
0
30000
4.39
A
1415889
D
Common Stock
2022-01-04
4
F
0
6658
19.78
D
1409231
D
Common Stock
2022-01-04
4
M
0
7142
0.25
A
1416373
D
Common Stock
2022-01-04
4
F
0
90
19.78
D
1416283
D
Stock Option (right to buy)
19.78
2022-01-03
4
A
0
9000
0
A
2032-01-03
Common Stock
9000
9000
D
Stock Option (right to buy)
4.39
2022-01-04
4
M
0
30000
0
D
2020-07-01
2030-07-01
Common Stock
30000
0
D
Stock Option (right to buy)
0.25
2022-01-04
4
M
0
7142
0
D
2018-04-06
2028-04-06
Common Stock
7142
0
D
Reflects 6,658 shares withheld by issuer at the market price of $19.78 per share less an exercise price of $4.39 per share to fund the cashless exercise of 30,000 options.
Reflects 90 shares withheld by issuer at the market price of $19.78 per share less an exercise price of $0.25 per share to fund the cashless exercise of 7,142 options.
The stock option shall vest in eight consecutive quarterly installments of 1,125 shares each on the 3rd day of April, July, October and January of each year, commencing April 3, 2022, and continuing through January 3, 2024.
/s/ Jeffrey McGroarty, Attorney-in-Fact for Michael Hoffman
2022-01-05